Pliant Therapeutics (PLRX)
(Delayed Data from NSDQ)
$12.14 USD
+0.09 (0.75%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $12.13 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Pliant Therapeutics, Inc. [PLRX]
Reports for Purchase
Showing records 21 - 29 ( 29 total )
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pliant Receives $4M Milestone Payment From Novartis Partnership; Two Abstracts Featured at ILC 2022; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap; Approaching Clinical Inflection Point With Phase 2a INTEGRIS-IPF Study Data Readout in Mid-2022; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PLN-74809 Granted Fast Track Designation; Five Presentations Scheduled For ATS 2022 Conference; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap: PLN-74809 Off to a Quick Start in 2022; Next Up Is INTEGRIS-IPF Top-Line Data in Mid-2022; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Phase 2a Study of High-Dose PLN-74809 Begins After Safety Confirmed by DSMB; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updates on Lead IPF Program and 2022 Expected Milestones; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; Early IPF Read-through Data in 1Q22; First-in- Patient Data in Mid-2022 Poised as Major Catalyst; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Leading the Development of a Novel Class of Oral Integrin Inhibitors to Treat Fibrosis; Initiate Buy, $45 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E